LivingGLP1
Study S002170

Clinical Assessment of Semaglutide-Induced Weight Reduction in Obese Populations

ClinicalTrials.gov record

Registration

Registration
NCT06825793
Study type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Status
NOT_YET_RECRUITING
Enrollment
56
Start
2025-02-20
Primary completion
2026-12-31
Lead sponsor
Beijing Chao Yang Hospital
Conditions
Obesity
Interventions
DRUG:Semaglutide Subcutaneous Injection
Results posted
FALSE

Registered primary outcomes

  • Body weight [Weight changes will be measured at the following time points: before treatment, and at weeks 4, 8, 12, 16, 20, 24, and 28 after treatment]
  • Gut microbiota [Gut microtioba will be measured at the following time points: before treatment, and at weeks 4, 8, 12, 16, 20, 24, and 28 after treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.